Different diagnostic methods for biliary tract cancer: A review

Abstract

Cholangiocarcinoma (CCA) is a primary malignant tumor originating from the epithelium of the bile duct mucosa. It is the second most common primary tumor of the liver and biliary tract. Based on tumor location, CCA is classified as intrahepatic and extrahepatic. Clinical diagnosis relies on imaging techniques (ultrasonography, computed tomography [CT], magnetic resonance imaging [MRI]), while the final diagnosis is confirmed through histopathological examination of biopsy, brush swab, or post-operative samples. Imaging plays a critical role in diagnosing, staging, and guiding the treatment of biliary cancers. Key imaging methods include magnetic resonance cholangiopancreatography (MRI with MRCP), endoscopic retrograde cholangiopancreatography, endoscopic ultrasound (EUS), and positron emission tomography (PET). Selecting the most suitable diagnostic tool is challenging due to the distinct properties of each method, which are tailored to different diseases and stages of diagnosis or treatment. For example, MRCP provides superior visualization of biliary tract narrowing/dilatation compared to direct cholangiography (ERC) and is more effective in assessing tumor extent. Ultrasound is useful for initial evaluation of bile duct and gallbladder tumors and for identifying bile duct dilatation. CT is effective for detecting focal lesions and staging cancer progression, while MRI is considered the gold standard for tumor visualization. EUS offers a detailed assessment of extrahepatic bile ducts, gallbladder, hepatic hilar structures, local lymph nodes, and vessels. Although ERC allows biopsy or smear collection, it does not assess tumor extent. PET is valuable for detecting distant metastases, monitoring treatment efficacy, and evaluating recurrence. This review focuses on the role of various imaging techniques in the diagnosis, staging, treatment response prediction, and therapy of CCA.

Keywords

Cholangiocarcinoma / Biliary tract cancer / Image-guided therapeutics

knowledgments

None.

Funding

None.

Conflict of interest

The authors declare no conflicts of interest.

Author contributions

Conceptualization: Zakariya Abdi Yakub, Justyna Magdalena Łabądź, David Aebisher, Paweł Woźnicki, Klaudia Dynarowicz, Angelika Myśliwiec, Dorota Bartusik-Aebisher

Writing - original draft: Justyna Magdalena Łabądź, David Aebisher, Paweł Woźnicki, Klaudia Dynarowicz, Dorota Bartusik-Aebisher

Writing - review & editing: Zakariya Abdi Yakub, Justyna Magdalena Łabądź, David Aebisher, Paweł Woźnicki, Klaudia Dynarowicz, Angelika Myśliwiec, Dorota Bartusik-Aebisher

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data

Data are available within the article.

References

[1] Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis of cholangiocarcinoma. BMC Cancer. 2019; 19(1):185. doi: 10.1186/s12885-019-5391-0

[2] Blechacz BR, Gores GJ. Cholangiocarcinoma Clin Liver Dis. 2008; 12(1):131-150, ix. doi: 10.1016/j.cld.2007.11.003

[3] Sempoux C, Jibara G, Ward SC, et al. Intrahepatic cholangiocarcinoma: New insights in pathology. Semin Liver Dis. 2011;31:49-60. doi: 10.1055/s-0031-1272839

[4] Yazici C, Niemeyer DJ, Iannitti DA, Russo MW. Hepatocellular carcinoma and cholangiocarcinoma: An update. Expert Rev Gastroenterol Hepatol. 2014; 8(1):63-82. doi: 10.1586/17474124.2014.852468

[5] Acalovschi M. Cholangiocarcinoma: Risk factors, diagnosis and management. Rom J Intern Med. 2004; 42(1):41-58.

[6] Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol. 2022; 77(6):1690-1698. doi: 10.1016/j.jhep.2022.07.022

[7] Khan AS, Dageforde LA. Cholangiocarcinoma Surg Clin North Am. 2019; 99(2):315-335. doi: 10.1016/j.suc.2018.12.004

[8] Krasinskas AM. Cholangiocarcinoma. Surg Pathol Clin. 2018; 11(2):403-429. doi: 10.1016/j.path.2018.02.005

[9] Kendall T, Verheij J, Gaudio E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39 (Suppl 1):7-18. doi: 10.1111/liv.14093

[10] Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol. 2023;2023:107064. doi: 10.1016/j.ejso.2023.107064

[11] Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013; 145(6):1215-1229. doi: 10.1053/j.gastro.2013.10.013

[12] Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 2019;39Suppl 1:19-31. doi: 10.1111/liv.14095

[13] Cadamuro M Strazzabosco M. Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention. Adv Cancer Res. 2022; 156:39-73. doi: 10.1016/bs.acr.2022.02.001

[14] Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006; 3(1):33-42.

[15] Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016; 122(9):1349-1369. doi: 10.1002/cncr.29692

[16] Surya H, Abdullah M, Nelwan EJ, et al. Current updates on diagnosis and management of cholangiocarcinoma: From surgery to targeted therapy. Acta Med Indones. 2023; 55(3):361-370.

[17] Banales JM, Marin JJ, Lamarca A, et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020; 17(9):557-588. doi: 10.1038/s41575-020-0310-z

[18] Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013; 11(1):13-21.e1; quiz e3-4. doi: 10.1016/j.cgh.2012.09.009

[19] Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014; 383(9935):2168-2179. doi: 10.1016/S0140-6736(13)61903-0

[20] Sarcognato S, Sacchi D, Fassan M, et al. Cholangiocarcinoma. Pathologica. 2021; 113(3):158-169. doi: 10.32074/1591-951X-252

[21] Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022; 76(5):1109-1121. doi: 10.1016/j.jhep.2021.12.010

[22] Gatto M, Bragazzi MC, Semeraro R, et al. Cholangiocarcinoma: Update and future perspectives. Dig Liver Dis. 2010; 42(4):253-260. doi: 10.1016/j.dld.2009.12.008

[23] Oliverius M, Havlůj L, Hajer J, Soumarova R, Hrudka J, Gurlich R. Surgery for cholangiocarcinoma. Cas Lek Cesk. 2019; 158(2):73-77. doi: 10.1111/liv.14089

[24] Giovinazzo F, Pascale MM, Cardella F, et al. Current perspectives in liver transplantation for perihilar cholangiocarcinoma. Curr Oncol. 2023; 30(3):2942-2953. doi: 10.3390/curroncol30030225

[25] Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2009; 69(3):259-270. doi: 10.1016/j.critrevonc.2008.09.008

[26] Fabrega-Foster K, Ghasabeh MA, Pawlik TM, Kamel IR. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017; 6:67-78. doi: 10.21037/hbsn.2016.12.10

[27] Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011; 8(9):512-522. doi: 10.1038/nrgastro.2011.131

[28] Kawashima H, Ohno E, Ishikawa T, et al. Endoscopic management of perihilar cholangiocarcinoma. Dig Endosc. 2022; 34(6):1147-1156. doi: 10.1111/den.14317

[29] Hamaoka M, Kozaka K, Matsui O, et al. Early detection of intrahepatic cholangiocarcinoma. Jpn J Radiol. 2019; 37(10):669-684. doi: 10.1007/s11604-019-00860-0

[30] Coronel M, Lee JH, Coronel E. Endoscopic ultrasound for the diagnosis and staging of biliary malignancy. Clin Liver Dis. 2022; 26(1):115-125. doi: 10.1016/j.cld.2021.08.010

[31] Saleh M, Virarkar M, Bura V, et al. Intrahepatic cholangiocarcinoma: Pathogenesis, current staging, and radiological findings. Abdom Radiol (NY). 2020; 45(11):3662-3680. doi: 10.1007/s00261-020-02559-7

[32] Yao D, Kunam VK, Li X. A review of the clinical diagnosis and therapy of cholangiocarcinoma. J Int Med Res. 2014; 42(1):3-16. doi: 10.1177/0300060513505488

[33] Rayubkul J, Laohasiriwong W, Thinkhamrop B, Mahato RK, Khantikeo N, Pongpanich S. Prevalence of suspected cholangiocarcinoma based on ultrasonography screening and its associated factors in Northeastern Thailand. Kathmandu Univ Med J (KUMJ). 2022; 20(79):254-259.

[34] Hann LE, Greatrex KV, Bach AM, Fong Y, Blumgart LH. Cholangiocarcinoma at the hepatic hilus: Sonographic findings. AJR Am J Roentgenol. 1997; 168(4):985-989. doi: 10.2214/ajr.168.4.9124155

[35] Bloom CM, Langer B, Wilson SR. Role of US in the detection, characterization, and staging of cholangiocarcinoma. Radiographics. 1999; 19(5):1199-1218. doi: 10.1148/radiographics.19.5.g99se081199

[36] Robledo R, Muro A, Prieto ML. Extrahepatic bile duct carcinoma: US characteristics and accuracy in demonstration of tumors. Radiology. 1996; 198(3):869-873. doi: 10.1148/radiology.198.3.8628885

[37] Sungkasubun P, Siripongsakun S, Akkarachinorate K, et al. Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: A population-based prospective study of 4,225 subjects in an endemic area. BMC Cancer. 2016;16:346. doi: 10.1186/s12885-016-2390-2

[38] Chung YE, Kim MJ, Park YN, et al. Varying appearances of cholangiocarcinoma: Radiologic-pathologic correlation. Radiographics. 2009; 29(3):683-700. doi: 10.1148/rg.293085729

[39] Thinkhamrop K, Khuntikeo N, Chamadol N, Suwannatrai AT, Phimha S, Kelly M. Associations between ultrasound screening findings and cholangiocarcinoma diagnosis in an at-risk population. Sci Rep. 2022; 12(1):13513. doi: 10.1038/s41598-022-17794-9

[40] Dietrich CF, Tannapfel A, Jang HY, Kim TK, Burns PN, Dong Y. Ultrasound imaging of hepatocellular adenoma using the new histology classification. Ultrasound Med Biol. 2019; 45:1-10. doi: 10.1016/j.ultrasmedbio.2018.06.015

[41] Xu HX. Contrast-enhanced ultrasound in the biliary system: Potential uses and indications. World J Radiol. 2009; 1(1):37-44. doi: 10.4329/wjr.v1.i1.37

[42] Conti CB, Cavalcoli F, Fraquelli M, Conte D, Massironi S. Ultrasound elastographic techniques in focal liver lesions. World J Gastroenterol. 2016; 22(9):2647-2656. doi: 10.3748/wjg.v22.i9.2647

[43] Massironi S, Conte D, Sciola V, et al. Contrast-enhanced ultrasonography in evaluating hepatic metastases from neuroendocrine tumours. Dig Liver Dis. 2010; 42(9):635-641. doi: 10.1016/j.dld.2010.01.009

[44] Ringe KI, Wacker F. Radiological diagnosis in cholangiocarcinoma: Application of computed tomography, magnetic resonance imaging, and positron emission tomography. Best Pract Res Clin Gastroenterol. 2015; 29(2):253-265. doi: 10.1016/j.bpg.2015.02.004

[45] Kim SY. Preoperative radiologic evaluation of cholangiocarcinoma. Korean J Gastroenterol. 2017; 69(3):159-163. doi: 10.4166/kjg.2017.69.3.159

[46] Raghavan K, Jeffrey RB, Patel BN, DiMaio MA, Willmann JK, Olcott EW. MDCT diagnosis of perineural invasion involving the celiac plexus in intrahepatic cholangiocarcinoma: Preliminary observations and clinical implications. AJR Am J Roentgenol. 2015; 205(6):W578-584. doi: 10.2214/AJR.15.14607

[47] Zhu Y, Mao Y, Chen J, Qiu Y, Wang Z, He J. Preoperative computed tomography features of intrahepatic cholangiocarcinoma for predicting lymph node metastasis and overall survival. J Comput Assist Tomogr. 2019; 43(5):729-735. doi: 10.1097/RCT.0000000000000922

[48] Olthof SC, Othman A, Clasen S, Schraml C, Nikolaou K, Bongers M. Imaging of cholangiocarcinoma. Visc Med. 2016; 32(6):402-410. doi: 10.1159/000453009

[49] Nam JG, Lee JM, Joo I, et al. Intrahepatic mass-forming cholangiocarcinoma: Relationship between computed tomography characteristics and histological subtypes. J Comput Assist Tomogr. 2018; 42(3):340-349.

[50] Aherne EA, Pak LM, Goldman DA, et al. Intrahepatic cholangiocarcinoma: Can imaging phenotypes predict survival and tumor genetics? Abdom Radiol (NY). 2018; 43(10):2665-2672. doi: 10.1007/s00261-018-1505-4

[51] Chen HW, Lai EC, Pan AZ, Chen T, Liao S, Lau WY. Preoperative assessment and staging of hilar cholangiocarcinoma with 16-multidetector computed tomography cholangiography and angiography. Hepatogastroenterology. 2009; 56(91-92):578-583.

[52] Kim HJ, Lee DH, Lim JW, Ko YT. Multidetector computed tomography in the preoperative workup of hilar cholangiocarcinoma. Acta Radiol. 2009; 50(8):845-853. doi: 10.1080/02841850903092366

[53] Endo I, Matsuyama R, Mori R, et al. Imaging and surgical planning for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2014; 21(8):525-532. doi: 10.1002/jhbp.75

[54] Zhang Y, Uchida M, Abe T, Nishimura H, Hayabuchi N, Nakashima Y. Intrahepatic peripheral cholangiocarcinoma: Comparison of dynamic CT and dynamic MRI. J Comput Assist Tomogr. 1999; 23(5):670-677. doi: 10.1097/00004728-199909000-00004

[55] Park HM, Jang HY, Lee DE, et al. Prognostic impact of tumor vascularity on CT in resectable intrahepatic cholangiocarcinoma. HPB (Oxford). 2022; 24(3):359-369. doi: 10.1016/j.hpb.2021.06.424

[56] Park HJ, Park B, Park SY, et al. Preoperative prediction of postsurgical outcomes in mass-forming intrahepatic cholangiocarcinoma based on clinical, radiologic, and radiomics features. Eur Radiol. 2021; 31(11):8638-8648. doi: 10.1007/s00330-021-07926-6

[57] Wakiya T, Ishido K, Kimura N, et al. CT-based deep learning enables early postoperative recurrence prediction for intrahepatic cholangiocarcinoma. Sci Rep. 2022; 12(1):8428. doi: 10.1038/s41598-022-12604-8

[58] Bliznakova K, Kolev N, Buliev I, et al. Computer aided preoperative evaluation of the residual liver volume using computed tomography images. J Digit Imaging. 2015; 28(2):231-239. doi: 10.1007/s10278-014-9737-5

[59] Sainani NI, Catalano OA, Holalkere NS, Zhu AX, Hahn PF, Sahani DV. Cholangiocarcinoma: Current and novel imaging techniques. Radiographics. 2008; 28(5):1263-1287. doi: 10.1148/rg.285075183

[60] Fred HL. Drawbacks and limitations of computed tomography: Views from a medical educator. Tex Heart Inst J. 2004; 31(4):345-348.

[61] Vilgrain V, Van Beers BE, Flejou JF, et al. Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr. 1997; 21(1):59-65. doi: 10.1097/00004728-199701000-00012

[62] Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging. 2015; 42(5):1165-1179. doi: 10.1002/jmri.24810

[63] Zhimin G, Noor H, Jian-Bo Z, Lin W, Jha RK. Advances in diagnosis and treatment of hilar cholangiocarcinoma--a review. Med Sci Monit. 2013; 19:648-656. doi: 10.12659/MSM.889379

[64] Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis. 2004; 24(2):155-164. doi: 10.1055/s-2004-828892

[65] Masselli G, Gualdi G. Hilar cholangiocarcinoma: MRI/ MRCP in staging and treatment planning. Abdom Imaging. 2008; 33(4):444-451. doi: 10.1007/s00261-007-9281-6

[66] Kim DW, Kim SY, Yoo C, Hwang DW. Update on biliary cancer imaging. Radiol Clin North Am. 2022; 60(5):825-842. doi: 10.1016/j.rcl.2022.05.001

[67] Xu Y, Ye F, Li L, et al. MRI-based radiomics nomogram for preoperatively differentiating intrahepatic mass-forming cholangiocarcinoma from resectable colorectal liver metastases. Acad Radiol. 2023; 30(9):2010-2020. doi: 10.1016/j.acra.2023.04.030

[68] Zhang J, Wu Z, Zhao J, et al. Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival. Eur Radiol. 2021; 31(6):3661-3672. doi: 10.1007/s00330-020-07524-y

[69] Sheng R, Huang X, Jin K, et al. Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma. Eur Radiol. 2022; 32(8):5156-5165. doi: 10.1007/s00330-022-08679-6

[70] Koh J, Chung YE, Nahm JH, et al. Intrahepatic mass-forming cholangiocarcinoma: Prognostic value of preoperative gadoxetic acid-enhanced MRI. Eur Radiol. 2016; 26(2):407-416. doi: 10.1007/s00330-015-3846-5

[71] Wang L, Liu J, Zeng Y, Shu J. The value of an MRI-based radiomics model in predicting the survival and prognosis of patients with extrahepatic cholangiocarcinoma. Cancer Med. 2024; 13(1):e6832. doi: 10.1002/cam4.6832

[72] Xin Y, Liu Q, Zhang J, et al. Hilar cholangiocarcinoma: Value of high-resolution enhanced magnetic resonance imaging for preoperative evaluation. J Cancer Res Ther. 2020; 16(7):1634-1640. doi: 10.4103/jcrt.JCRT_140_20

[73] Min JH, Kim YK, Choi SY, et al. Intrahepatic mass-forming cholangiocarcinoma: Arterial enhancement patterns at MRI and prognosis. Radiology. 2019; 290(3):691-699. doi: 10.1148/radiol.2018181485

[74] Vanderveen KA, Hussain HK. Magnetic resonance imaging of cholangiocarcinoma. Cancer Imaging. 2004; 4(2):104-115. doi: 10.1102/1470-7330.2004.0018

[75] Kovač JD, Janković A, Đikić-Rom A, Grubor N, Antić A, Dugalić V. Imaging spectrum of intrahepatic mass-forming cholangiocarcinoma and its mimickers: How to differentiate them using MRI. Curr Oncol. 2022; 29(2):698-723. doi: 10.3390/curroncol29020061

[76] Singh A, Siddiqui UD. The role of endoscopy in the diagnosis and management of cholangiocarcinoma. J Clin Gastroenterol. 2015; 49(9):725-737. doi: 10.1097/MCG.0000000000000390

[77] Voigtlander T, Lankisch TO. Endoscopic diagnosis of cholangiocarcinoma: From endoscopic retrograde cholangiography to bile proteomics. Best Pract Res Clin Gastroenterol. 2015; 29(2):267-275. doi: 10.1016/j.bpg.2015.02.005

[78] Vogel A, Wege H, Caca K, Nashan B, Neumann U. The diagnosis and treatment of cholangiocarcinoma. Dtsch Arztebl Int. 2014; 111(44):748-754. doi: 10.3238/arztebl.2014.0748

[79] Rizvi S, Gores GJ. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion. 2014; 89(3):216-224. doi: 10.1159/000360791

[80] Cowling MG, Adam AN. Internal stenting in malignant biliary obstruction. World J Surg. 2001; 25(3):355-359; discussion359-361. doi: 10.1007/s002680020384

[81] Rizvi S, Eaton J, Yang JD, Chandrasekhara V, Gores GJ. Emerging technologies for the diagnosis of perihilar cholangiocarcinoma. Semin Liver Dis. 2018; 38(2):160-169. doi: 10.1055/s-0038-1655775

[82] Kalaitzakis E, Levy M, Kamisawa T, et al. Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma. Clin Gastroenterol Hepatol. 2011; 9(9):800-803.e2. doi: 10.1016/j.cgh.2011.05.019

[83] Chaves J., Fernandez Y., Viesca M., Arvanitakis M. Using Endoscopy in the Diagnosis of Pancreato-Biliary Cancers. Cancers (Basel). 2023 Jun 28;15(13):3385.

[84] Jo JH, Cho CM, Jun JH, et al. Same-session endoscopic ultrasound-guided fine needle aspiration and endoscopic retrograde cholangiopancreatography-based tissue sampling in suspected malignant biliary obstruction: A multicenter experience. J Gastroenterol Hepatol. 2019; 34(4):799-805. doi: 10.1111/jgh.14528

[85] Levy MJ, Heimbach JK, Gores GJ. Endoscopic ultrasound staging of cholangiocarcinoma. Curr Opin Gastroenterol. 2012; 28(3):244-252. doi: 10.1097/MOG.0b013e32835005bc

[86] Strongin A, Singh H, Eloubeidi MA, Siddiqui AA. Role of endoscopic ultrasonography in the evaluation of extrahepatic cholangiocarcinoma. Endosc Ultrasound. 2013; 2(2):71-76. doi: 10.4103/2303-9027.117690

[87] Orzan RI, Pojoga C, Agoston R, Seicean R, Seicean A. Endoscopic ultrasound in the diagnosis of extrahepatic cholangiocarcinoma: What do we know in 2023? Diagnostics (Basel). 2023; 13(6):1023. doi: 10.3390/diagnostics13061023

[88] Onda S, Ogura T, Kurisu Y, et al. EUS-guided FNA for biliary disease as first-line modality to obtain histological evidence. Therap Adv Gastroenterol. 2016; 9(3):302-312. doi: 10.1177/1756283X15625584

[89] Shin DW, Moon SH, Kim JH. Diagnosis of cholangiocarcinoma. Diagnostics (Basel). 2023; 13(2):233. doi: 10.3390/diagnostics13020233

[90] Harewood GC. Endoscopic tissue diagnosis of cholangiocarcinoma. Curr Opin Gastroenterol. 2008; 24(5):627-630. doi: 10.1097/MOG.0b013e32830bf7e1

[91] De Jong DM, van de Vondervoort S, Dwarkasing RS, et al. Endoscopic ultrasound in patients with resectable perihilar cholangiocarcinoma: Impact on clinical decision-making. Endosc Int Open. 2023; 11(2):E162-E168. doi: 10.1055/a-2005-3679

[92] Nguyen K, Sing JT Jr. Review of endoscopic techniques in the diagnosis and management of cholangiocarcinoma. World J Gastroenterol. 2008; 14(19):2995-2999. doi: 10.3748/wjg.14.2995

[93] Busing KA, Schonberg SO, Brade J, Wasser K. Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumors and healthy organs on 18F-FDG PET/CT. Nucl Med Biol. 2013; 40(2):206-213. doi: 10.1016/j.nucmedbio.2012.10.014

[94] Annunziata S, Caldarella C, Pizzuto DA, et al. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: A metaanalysis. Biomed Res Int. 2014;2014:247693. doi: 10.1155/2014/247693

[95] Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004; 8(1):90-97. doi: 10.1016/j.gassur.2003.10.003

[96] Kim JY, Kim MH, Lee TY, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: A prospective study compared with conventional imaging. Am J Gastroenterol. 2008; 103(5):1145-1151. doi: 10.1111/j.1572-0241.2007.01710.x

[97] Breitenstein S, Apestegui C, Clavien PA. Positron emission tomography (PET) for cholangiocarcinoma. HPB (Oxford). 2008; 10(2):120-121. doi: 10.1080/13651820801992583

[98] Lee Y, Yoo IR, Boo SH, Kim H, Park HL, Hyun OJ. The role of F-18 FDG PET/CT in intrahepatic cholangiocarcinoma. Nucl Med Mol Imaging. 2017; 51(1):69-78. doi: 10.1007/s13139-016-0440-y

[99] Fiz F, Masci C, Costa G, et al. PET/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival. Eur J Nucl Med Mol Imaging. 2022; 49(10):3387-3400. doi: 10.1007/s00259-022-05765-1

[100] Jiang L, Tan H, Panje CM, Yu H, Xiu Y, Shi H. Role of 18FFDG PET/CT imaging in intrahepatic cholangiocarcinoma. Clin Nucl Med. 2016; 41(1):1-7. doi: 10.1097/RLU.0000000000000998

[101] Guniganti P, Kierans AS. PET/MRI of the hepatobiliary system: Review of techniques and applications. Clin Imaging. 2021; 71:160-169. doi: 10.1016/j.clinimag.2020.10.056

[102] Vaquero JJ, Kinahan P. Positron emission tomography: Current challenges and opportunities for technological advances in clinical and preclinical imaging systems. Annu Rev Biomed Eng. 2015;17:385-414. doi: 10.1146/annurev-bioeng-071114-040723

[103] Arslan E, Çermik TF. PET/CT variants and pitfalls in liver, biliary tract, gallbladder and pancreas. Semin Nucl Med. 2021; 51(5):502-518. doi: 10.1053/j.semnuclmed.2021.04.006

[104] Lan L, Zhang S, Xu T, et al. Prospective comparison of 68Ga-FAPI versus 18F-FDG PET/CT for tumor staging in biliary tract cancers. Radiology. 2022; 304(3):648-657. doi: 10.1148/radiol.213118

[105] Lamarca A, Barriuso J, Chander A, et al. 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J Hepatol. 2019; 71(1):115-129. doi: 10.1016/j.jhep.2019.01.038

[106] Goel S, Aggarwal A, Iqbal A, Gupta M, Rao A, Singh S. 18-FDG PET-CT should be included in preoperative staging of gall bladder cancer. Eur J Surg Oncol. 2020; 46(9):1711-1716. doi: 10.1016/j.ejso.2020.04.015

[107] Karagyozov P, Boeva I, Tishkov I. Role of digital single-operator cholangioscopy in the diagnosis and treatment of biliary disorders. World J Gastrointest Endosc. 2019; 11(1):31-40. doi: 10.4253/wjge.v11.i1.31

[108] Feng Y, Liang Y, Liu Y, et al. Digital cholangioscopy-assisted, direct visualization-guided, radiation-free, endoscopic retrograde intervention for cholelithiasis: Technical feasibility, efficacy, and safety. Surg Endosc. 2024; 38(3):1637-1646. doi: 10.1007/s00464-024-10684-3

[109] Wakai T, Nagahashi M, Shimada Y, Prasoon P, Sakata J. Genetic analysis in the clinical management of biliary tract cancer. Ann Gastroenterol Surg. 2020; 4(4):316-323. doi: 10.1002/ags3.12334

[110] Kato S. Tumour-agnostic therapy for pancreatic cancer and biliary tract cancer. Diagnostics (Basel). 2021; 11(2):252. doi: 10.3390/diagnostics11020252

[111] Mayerhoefer ME, Materka A, Langs G, et al. Introduction to radiomics. J Nucl Med. 2020; 61(4):488-495. doi: 10.2967/jnumed.118.222893

[112] Liu QP, Tang J, Chen YZ, et al. Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial. JHEP Rep. 2023; 5(7):100763. doi: 10.1016/j.jhepr.2023.100763

[113] Kocak B, Durmaz EŞ, Ateş E, Kılıckesmez O. Radiomics with artificial intelligence: A practical guide for beginners. Diagn Interv Radiol. 2019; 25(6):485-495. doi: 10.5152/dir.2019.19321

[114] Bo Z, Chen B, Yang Y, et al. Machine learning radiomics to predict the early recurrence of intrahepatic cholangiocarcinoma after curative resection: A multicentre cohort study. Eur J Nucl Med Mol Imaging. 2023; 50(8):2501-2513. doi: 10.1007/s00259-023-06184-6

[115] Gupta P, Kambadakone A, Sirohi B. Editorial: Role of imaging in biliary tract cancer: Diagnosis, staging, response prediction and image-guided therapeutics. Front Oncol. 2024;14:1387531. doi: 10.3389/fonc.2024.1387531

[116] Fernandez Y, Viesca M, Arvanitakis M. Early diagnosis and management of malignant distal biliary obstruction: A review on current recommendations and guidelines. Clin Exp Gastroenterol. 2019; 12:415-432. doi: 10.2147/CEG.S195714

[117] Cha JM, Kim MH, Jang SJ. Early bile duct cancer. World J Gastroenterol. 2007; 13(25):3409-3416. doi: 10.3748/wjg.v13.i25.3409

[118] Bao F, Liu J, Chen H, Miao L, Xu Z, Zhang G. Diagnosis biomarkers of cholangiocarcinoma in human bile: An evidence-based study. Cancers (Basel). 2022; 14(16):3921. doi: 10.3390/cancers14163921

[119] Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: A systematic review. Am J Gastroenterol. 2006; 101(3):513-23. doi: 10.1111/j.1572-0241.2006.00467.x